Hikma has made the next move to build up its nascent US biosimilars business by striking a deal with Gedeon Richter for its denosumab candidate.
Hikma has revealed the next piece that has been put in place as it seeks to build up a US biosimilars business, striking a licensing deal with Gedeon Richter that will allow Hikma to market exclusively the firm’s biosimilar rivals to the denosumab-based brands Prolia and Xgeva in the US.
Gedeon Richter’s proposed biosimilars – which will be used to treat osteoporosis and fractures due to bone metastasis respectively –...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
